drug they were working on failed to meet the primary end point of its clinical trial since then alkermesrking its way higher but it's 25 bucks below it was trading before everything got dinged at the beginning of 2016. maybe that change this is year, though the company had several major catalysts ahead including the same depression drug coming up for fresh review they have three drugs in phase three trials plus the company has two drugs on the market, vivitrol for recovery addicts and a long acting compound for people with schizophrenia and psychotic disorder and this morning the ceo tweeted that 2018 could be a transformative year. we know the company is presenting tomorrow at the j.p. morgan health care conference, maybe we can get preview so let's get a closer look with richard pops, the ceo of alkermes welcome back to "mad money." >> good to be with you, jim. >> richard, you did something bold today and i know you don't do things bold unless you can back it up you said 2018 would be a transformative year of milestones, please elaborate. >> you know how it is in biotech. it takes many